Aridis Pharmaceuticals, Inc., announced today that it has appointed seasoned pharmaceutical executive Robert Ruffolo, Jr., Ph.D., D.Sc.(h), D.Eng.(h), F.C.P.P....
Aridis Pharmaceuticals, Inc., announced today that in addition to the previously announced European Patent Office (EPO) patent issuance, the U.S. Patent and Trademark Office has issued Aridis’ patent covering composition-of-matter, method of production and method of treatment for AR-301 (SalvecinTM)....
Aridis Pharmaceuticals, Inc., announced today that the Company will present at BIO CEO & Investor Conference 2016, taking place in New York February 8-9, 2016....
Aridis Pharmaceuticals, Inc., announced today positive Phase 1 clinical results for its fully human monoclonal antibody Aerucin® for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Gram negative bacteria Pseudomonas aeruginosa....
Aridis Pharmaceuticals, Inc., announced today that the Company will present at the Biotech Showcase™ 2016, taking place in San Francisco, CA, on January 11–13, 2016....
Aridis Pharmaceuticals, Inc., announced today that it has secured several grants which bring Aridis’ total non-dilutive funding in excess of $40 million. The grants were awarded by the National Institutes of Health (NIH) and through its Small Business Innovations Research (SBIR) program. ...
Aridis Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to AR-301, the Company's fully human anti-Staphylococcal alpha-toxin IgG1 monoclonal antibody (mAb). ...
Aridis Pharmaceuticals, Inc., announced today the appointment of Fred Kurland, a seasoned pharmaceutical executive, as the Company’s first Chief Financial Officer....
Aridis Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for AR-301, also referred to as Salvecin™, the company’s fully human anti-Staphylococcal α-toxin IgG1 monoclonal antibody being developed for the treatment of hospital-acquired and...
Aridis Pharmaceuticals, Inc., announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to its fully human monoclonal antibody Aerucin™ for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa....